×
About 2,683 results

ALLMedicine™ Burkitt Lymphoma Center

Research & Reviews  924 results

Factors associated with survival in patients with lymphoma and HIV: the largest cohort ...
https://doi.org/10.1097/QAD.0000000000003549
AIDS (London, England); Vargas JC, Marques MO et. al.

Mar 21st, 2023 - To analyze the factors associated with survival in the largest cohort of individuals with HIV and lymphoma so far described in Brazil. A retrospective, observational, multicenter study involving five institutions in São Paulo, Brazil. The medical ...

Spondyloarthritis and nonbacterial thrombotic endocarditis as paraneoplastic manifestat...
https://doi.org/10.1111/1756-185X.14651
International Journal of Rheumatic Diseases; Wang CY, Lee HC et. al.

Mar 21st, 2023 - Non-radiographic axial spondyloarthropathy (nr-axSpA) is a clinical diagnosis of symptoms matching inflammatory back pain criteria without radiological lesions at the sacroiliac joint. The frequency of an early nr-axSpA-like presentation in lympho...

Mosaic chromosomal alterations detected in men living with HIV and the relationship to ...
https://doi.org/10.1097/QAD.0000000000003545
AIDS (London, England); Lin SH, Khan SM et. al.

Mar 18th, 2023 - People living with HIV (PLWH) have elevated risk of non-Hodgkin lymphoma (NHL) and other diseases. Studying clonal hematopoiesis (CH), the clonal expansion of mutated hematopoietic stem cells, could provide insights regarding elevated NHL risk. Co...

Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
https://doi.org/10.6004/jnccn.2023.7004
Journal of the National Comprehensive Cancer Network : JN... Forlenza CJ, Chadburn A et. al.

Mar 11th, 2023 - Primary mediastinal B-cell lymphoma (PMBCL) is a rare but aggressive mature B-cell lymphoma that arises from thymic B cells and most commonly affects adolescents and young adults. PMBCL is now recognized by the WHO as a distinct entity from diffus...

see more →

Guidelines  2 results

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  38 results

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Mar 10th, 2023 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving ...
https://clinicaltrials.gov/ct2/show/NCT05206357

Mar 10th, 2023 - The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of rela...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Mar 6th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphom...
https://clinicaltrials.gov/ct2/show/NCT04970901

Feb 24th, 2023 - This is a Phase 1b, multi-center, open-label, multi-arm study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polatuzumab vedotin, or umbralisib in participants with relapsed...

see more →

News  104 results

FDA Grants Orphan Drug Designation to PCLX-001 for AML
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-pclx-001-for-aml

Oct 17th, 2022 - The FDA has granted an orphan drug designation (ODD) to PCLX-001 (DDD86481) for the treatment of patients with acute myeloid leukemia (AML).1 PCLX-001 is a first-in-class N-myristoylation (NMT) inhibitor that is currently being studied in non-H...

FDA Accepts sBLA for Polatuzumab Vedotin Plus R-CHP in Untreated DLBCL
https://www.onclive.com/view/fda-accepts-sbla-for-polatuzumab-vedotin-plus-r-chp-in-untreated-dlbcl

Aug 24th, 2022 - The FDA has accepted a supplemental biologics license application (sBLA) for the combination of polatuzumab vedotin-piiq (Polivy) and R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) as a treatment for patients with previ...

Epstein-Barr Virus Linked With Gastric Cancer
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/100193

Aug 12th, 2022 - A substantial proportion of gastric cancers worldwide was linked with the Epstein-Barr virus (EBV), according to a meta-analysis. In a pooled analysis involving over 68,000 patients with conventional gastric adenocarcinoma in 37 countries, EBV pre...

R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma
https://www.onclive.com/view/r-codox-m-r-ivac-fails-to-establish-superior-efficacy-over-da-epoch-r-in-high-risk-burkitt-lymphoma

Jun 12th, 2022 - Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma, according to results from a phase 3 trial (EUDRACT 2013-004394-27).1 Study...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

see more →

Patient Education  4 results see all →